The effect of combined β2-agonist and anticholinergic inhaled therapy in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004
Concomitant use of low-dose inhaled corticosteroids and a long-acting bronchodilatator visavi doubling the dose of inhaled corticosterod in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 98s Year: 2001
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids Source: Breathe 2010; 6: 365 Year: 2010
Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007
Inhaled corticosteroid combined with long-acting bronchodilator versus long-acting bronchodilator alone for older patients with COPD Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015
Low adherence to inhaled corticosteroids/long-acting ß2 -agonists and biologic treatment in severe asthmatics Source: ERJ Open Res, 6 (2) 00017-2020; 10.1183/23120541.00017-2020 Year: 2020
Switching asthma patients using high-dose inhaled steroids to budesonide/formoterol maintenance and reliever therapy Source: Annual Congress 2010 - Management of airway disease Year: 2010
Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004
Effects of montelukast on tapering inhaled corticosteroids in patients with asthma Source: Eur Respir J 2001; 18: Suppl. 33, 260s Year: 2001
Effects of montelukast on tapering inhaled corticosteroids in patients with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 407s Year: 2002
Adding slow-released theophyllne to inhaled corticosteroids in the treatment of mild persistent asthma Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007
The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA) Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Efficacy of systemic corticosteroids in refractory asthmatics showing no bronchial reversibility with high-dose inhaled corticosteroids or β2 agonist inhalation Source: Annual Congress 2010 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2010
Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001
Comparison of inhaled corticosteroid combined with theophylline and double-dose inhaled corticosteroid in moderate-severe persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 127s Year: 2004
The anti-tussive effects of an inhaled LABA are maintained after chronic treatment Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018
The effects of addition montelukast to inhaled steroids in the regular treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001
Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 43s Year: 2001